tiprankstipranks
Circassia Pharmaceuticals PLC (GB:CIR)
LSE:CIR

Circassia Pharmaceuticals (CIR) Income Statement

0 Followers

Circassia Pharmaceuticals Income Statement

See GB:CIR’s key income statement, including revenue, expenses, profit, and income.
Income Statement
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
£ 27.90M£ 23.90M£ 34.60M£ 48.30M£ 46.30M
Cost of Revenue
£ 8.90M£ 7.60M£ 9.10M£ 8.90M£ 10.00M
Gross Profit
£ 19.00M£ 16.30M£ 25.50M£ 39.40M£ 36.30M
Operating Expense
£ 23.30M£ 33.60M£ 89.30M£ 76.60M£ 118.60M
Operating Income
£ -4.30M£ -17.30M£ -63.80M£ -37.20M£ -82.30M
Net Non Operating Interest Income Expense
£ -300.00K£ -200.00K£ -100.00K£ -11.70M£ -2.40M
Other Income Expense
-----
Pretax Income
£ -2.10M£ -18.40M£ -27.60M£ -55.80M£ -74.20M
Tax Provision
£ -4.40M£ 8.40M£ -10.80M£ -9.20M£ -13.70M
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
£ 3.60M£ -33.50M£ -48.30M£ -117.10M£ -99.10M
Basic EPS
£ 0.01£ -0.09£ -0.13£ -0.34£ -0.31
Diluted EPS
£ 0.01£ -0.09£ -0.13£ -0.34£ -0.31
Basic Average Shares
£ 412.60M£ 381.86M£ 373.70M£ 344.35M£ 319.54M
Diluted Average Shares
£ 435.83M£ 381.86M£ 373.70M£ 344.35M£ 319.54M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
--£ -0.11£ -0.08£ -0.11
Reported Normalized Diluted E P S
---£ 0.08£ 0.11
Rent Expense Supplemental
---£ 800.00K£ 800.00K
Total Expenses
£ 32.20M£ 41.20M£ 98.40M£ 85.50M£ 128.60M
Net Income From Continuing And Discontinued Operation
£ 3.60M£ -33.50M£ -48.30M£ -117.10M£ -99.10M
Normalized Income
£ 1.73M£ -26.80M£ -16.80M£ -47.52M£ -63.19M
Interest Expense
£ 100.00K£ 100.00K£ 100.00K£ 11.90M£ 2.70M
EBIT
£ -2.00M£ -18.30M£ -27.50M£ -43.90M£ -71.50M
EBITDA
£ 2.90M£ -9.30M£ -12.30M£ -39.50M£ -66.60M
Currency in GBP

Circassia Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis